Introduction
Since the first description of a novel, flexible, single-arm robotic surgical system (da Vinci SP Surgical system, Model SP999; Intuitive Surgical Inc.) was first evaluated clinically in 2010 on 19 patients undergoing urological surgery [1] . Further technical refinements have been developed in this robotic system with recent publications containing a detailed description of the current design of the robot and cadaveric applications in transoral robotic surgery (TORS) [2, 3] . In brief, this next generation system incorporates a stereoscopic binocular camera and three 6 mm flexible instruments in a cannula of 2.5 cm diameter. The flexible robotic arms allow the instruments to be deployed from the oral cavity to the nasopharynx, oropharynx, hypopharynx, and larynx. Here, we describe the early results of the first ever clinical investigation into the feasibility and safety of this updated flexible single-arm robot, da Vinci SP (Intuitive Surgical Inc.), in TORS.
Methods

Study design
This was a prospective institutional review board approved, innovation, development, exploration, assessment, long-term study (IDEAL) phase 1 clinical trial conducted in accordance with the Declaration of Helsinki under the institutional review board and local regulatory body approval of The Abstract The aim of this study was to describe the early results of a phase 1 safety and feasibility clinical trial of the first clinical use of a novel robot for transoral robotic surgery (TORS)-the da Vinci SP (Intuitive Surgical Inc., Sunnyvale, CA, USA). Study design of this study is prospective clinical trial. The methods used in this study are prospective innovation, development, exploration, assessment, and longterm study phase 1 clinical trial. Early results of six patients underwent TORS with the da Vinci SP (Intuitive Surgical Inc., Sunnyvale, CA, USA) demonstrate access the nasopharynx, oropharynx, larynx, and hypopharynx. There were no conversions of the robotic surgical system. There were no serious adverse events or adverse events related to the use of the robot at 30-day follow-up for all six patients. The early results of this safety and feasibility trial of the da Vinci SP (Intuitive Surgical Inc., Sunnyvale, CA, USA) clearly demonstrate that the device is safe and that it is feasible in performing TORS to access the nasopharynx, oropharynx, larynx, and hypopharynx.
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Chinese University of Hong Kong. The study was registered on http://www.ClinicalTrials.gov (NCT03010813).
Study population
Both benign and malignant lesions of the head and neck were included with the first six cases, as shown in Table 1 .
Study endpoints
Primary endpoint included conversion rates and perioperative complications within 30 days following surgery. Secondary endpoints included operative time, blood loss, and pain scores as documented with a visual analogue scale.
Statistical analysis
The Fisher's exact test and Mann-Whitney U test will be used to compare categorical, and non-parametric data for the trial. A p value <0.05 was considered to be statistically significant.
Results
Among the first six enrolled patients, there were no conversions to alternative surgical approaches. There were no serious adverse events or adverse events related to the use of the da Vinci SP (Intuitive Surgical Inc., Sunnyvale, CA, USA). There were surgical complications in two patients unrelated to the robot use. Case number four, a patient who had previous radiotherapy and poor dentition had a fractured right lower molar that required a dental consultation. Case number five had a 1 cm laceration of the tongue from the mouthgag that resolved by itself on followup visits. 
Discussion
The early results of this safety and feasibility trial of the da Vinci SP (Intuitive Surgical Inc., Sunnyvale, CA, USA) clearly demonstrate that the device is safe and that it is feasible in performing transoral surgery to access the nasopharynx, oropharynx, larynx, and hypopharyngeal region. This has been achieved in a predominantly Southern Chinese population despite significantly different, in particular smaller cranio-facial measurements as compared to Caucasians [4] . A significant advantage offered by the da Vinci SP (Intuitive Surgical Inc., Sunnyvale, CA, USA) is the option to use three instruments to perform transoral endoscopic surgery. The working space within the instruments and camera is roughly the size of a tennis ball. This third arm replaces the need of an assistant to provide traction and counter traction and allows the surgeon to control these maneuvers to better dissect critical neurovascular structures. Other distinct advantages include the flexible camera enabled with digital zoom that allows magnification and easier visualization of lesions and the different compartments of the pharynx.
There are some limitations to the system; now, with the extra arm, there is less working space for an assistant to, in particular, aid with suction. However, this can be largely overcome with a suction catheter placed through the nasal cavity into the desired location. Another limitation is the lack of bone instrumentation to resect, in particular tumors of the nasopharynx and skull base.
Conclusion
The early results of the use of the novel single-port flexible robotic system, the da Vinci SP (Intuitive Surgical Inc., Sunnyvale CA, USA) demonstrate that the device is safe and feasible to use for TORS to access the nasopharynx, oropharynx, larynx, and hypopharynx. 
